Shares of Cellectis SA (NASDAQ:CLLS) have been given an average rating of “Hold” by the nine research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $42.67.
CLLS has been the subject of a number of research analyst reports. Nomura lifted their price target on Cellectis to $73.00 and gave the stock a “buy” rating in a report on Wednesday, March 14th. BidaskClub cut Cellectis from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 14th. Guggenheim initiated coverage on Cellectis in a report on Friday, March 16th. They set a “neutral” rating for the company. ValuEngine upgraded Cellectis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, Zacks Investment Research upgraded Cellectis from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a report on Tuesday, May 15th.
Shares of NASDAQ CLLS traded up $0.21 during mid-day trading on Friday, hitting $28.60. The company had a trading volume of 50,132 shares, compared to its average volume of 148,387. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -10.29 and a beta of 1.88. Cellectis has a one year low of $21.25 and a one year high of $38.85.
Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.01). Cellectis had a negative return on equity of 37.45% and a negative net margin of 337.45%. The business had revenue of $8.07 million for the quarter, compared to the consensus estimate of $9.53 million. sell-side analysts anticipate that Cellectis will post -2.59 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. Nexthera Capital LP acquired a new stake in Cellectis during the first quarter worth approximately $10,485,000. Point72 Asset Management L.P. acquired a new stake in Cellectis during the first quarter worth approximately $2,206,000. Ladenburg Thalmann Financial Services Inc. lifted its position in Cellectis by 1,300.0% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,600 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 5,200 shares during the last quarter. Jane Street Group LLC acquired a new stake in Cellectis during the first quarter worth approximately $1,539,000. Finally, A.R.T. Advisors LLC acquired a new stake in Cellectis during the first quarter worth approximately $799,000. Institutional investors and hedge funds own 16.76% of the company’s stock.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.